{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:18Z","timestamp":1791414618510,"version":"4.3.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1097\/01.ftd.0000245771.82720.c7","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T15:26:16Z","timestamp":1161185176000},"page":"678-685","source":"Crossref","is-referenced-by-count":78,"title":["A Rapid and Inexpensive Method for Anticipating Severe Toxicity to Fluorouracil and Fluorouracil-based Chemotherapy"],"prefix":"10.1097","volume":"28","author":[{"given":"Joseph","family":"Ciccolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Blanquicett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Blesius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"R2-18-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00007691-200210000-00002","article-title":"Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.","volume":"24","author":"Di Paolo","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R3-18-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-003-0330-z","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: Mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.","volume":"8","author":"Omura","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"R4-18-20210129","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.","volume":"40","author":"Van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"R5-18-20210129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"key":"R6-18-20210129","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R7-18-20210129","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R8-18-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(01)00359-0","article-title":"High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: Application to measurement of dihydropyrimidine dehydrogenase activity.","volume":"762","author":"Deporte-Fety","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R9-18-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R10-18-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1008337913456","article-title":"Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression.","volume":"11","author":"Takenoue","year":"2000","journal-title":"Ann Oncol"},{"key":"R11-18-20210129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: A potential biomarker for dihydropyrimidine dehydrogenase levels.","volume":"141","author":"Jiang","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R12-18-20210129","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","article-title":"Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients.","volume":"79","author":"Van Kuilenburg","year":"1999","journal-title":"Br J Cancer"},{"key":"R13-18-20210129","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R14-18-20210129","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/01.ftd.0000162016.11148.1b","article-title":"Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.","volume":"27","author":"Di Paolo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R15-18-20210129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.","volume":"823","author":"Remaud","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R16-18-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1570-0232(02)00009-0","article-title":"Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry.","volume":"769","author":"Jiang","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-18-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1570-0232(02)00239-8","article-title":"Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5-fluorouracil toxicity.","volume":"74","author":"Garg","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R18-18-20210129","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0091270004268911","article-title":"Important role of the dihydrouracil\/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.","volume":"44","author":"Jiang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R19-18-20210129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2710.2004.00569.x","article-title":"A simple and rapid High Performance Liquid Chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.","volume":"29","author":"Ciccolini","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R22-18-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2710.2003.00468.x","article-title":"A population pharmacokinetics of cisplatin after 120-h infusion: Application to routine adaptive control with feedback.","volume":"28","author":"Monjanel-Mouterde","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"R23-18-20210129","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0959-8049(98)00175-0","article-title":"Autoregulation of 5-fluorouracil metabolism.","volume":"34","author":"McLeod","year":"1998","journal-title":"Eur J Cancer"},{"key":"R24-18-20210129","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"},{"key":"R25-18-20210129","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","article-title":"High prevalence of the IVS14 + 1GA mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.","volume":"12","author":"Van Kuilenburg","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R28-18-20210129","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-03-0285","article-title":"Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.","volume":"10","author":"Bellibas","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R29-18-20210129","first-page":"626","article-title":"Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency.","volume":"148","author":"Hooiveld","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R30-18-20210129","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1158\/1078-0432.CCR-04-1497","article-title":"Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.","volume":"11","author":"Yonemori","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R31-18-20210129","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.1978.278","article-title":"Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.","volume":"38","author":"Hillcoat","year":"1978","journal-title":"Br J Cancer"},{"key":"R32-18-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","article-title":"Cisplatin nephrotoxicity.","volume":"23","author":"Arany","year":"2003","journal-title":"Semin Nephrol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006534-200607000-00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:15:15Z","timestamp":1785939315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200610000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000245771.82720.c7","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}